Toggle Main Menu Toggle Search

Open Access padlockePrints

Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion

Lookup NU author(s): Professor Anthony MoormanORCiD, Claire Schwab, Emily Winterman, Dr Frederik van DelftORCiD, Professor Christine Harrison FRCPath FMedSci



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons LtdPatients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).

Publication metadata

Author(s): Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A

Publication type: Article

Publication status: Published

Journal: British Journal of Haematology

Year: 2020

Volume: 191

Issue: 5

Pages: 844-851

Print publication date: 01/12/2020

Online publication date: 14/09/2020

Acceptance date: 17/08/2020

Date deposited: 06/01/2021

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: Blackwell Publishing Ltd


DOI: 10.1111/bjh.17093


Altmetrics provided by Altmetric


Funder referenceFunder name
Blood Cancer UK (formerly Bloodwise) for financial support